Vaxart (VXRT) 10-Q2017 Q2 Quarterly report

Filed: 6 Feb 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abroad, advantage, affirmative, affirmed, afford, afforded, authorize, authorized, average, avoid, biological, call, carefully, carrier, cease, cell, certainty, certificate, circumvent, circumvented, clarified, cold, combining, committed, complex, compulsory, coverage, criteria, crystalline, decline, deductible, degree, description, detect, device, diminish, discourage, discover, discretion, EU, expand, expiratory, extend, extensive, factual, fall, fixed, fluctuation, forfeited, harm, harmed, hematopoietic, hospitalization, hostile, Hovione, HSCT, insurance, interference, invalidate, invalidated, invention, Investigational, issuance, Law, lifting, lose, merging, met, mortality, owed, ownership, pill, poison, power, priority, private, profile, progression, prohibit, proportion, protracted, provision, proxy, Readout, reimburse, rely, removal, remove, replace, replaced, resolution, restated, RV, seek, shedding, small, stem, stockholder, substantive, suggested, superseded, Symptom, technology, tract, transplant, uncertain, unpredictable, valid, viable, virological, visit, volume, vote, voting, Wisconsin

Removed: appeal, ascending, depreciation, dose, dosing, expiration, healthy, includingthe, inPart, multiple, outcome, pharmacokinetic, response

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VXRT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Aviragen Therapeutics, Inc. (“the Company”) for the quarterly period ended December 31, 2016 (the “Report”), I, Joseph M. Patti, Chief Executive Officer of the Company, and Mark P. Colonnese, Chief Financial Officer of the Company each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

●

To my knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

●

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 6, 2017	By:	/s/ Joseph M. Patti
		Joseph M. Patti
		Chief Executive Officer
		(Principal Executive Officer)


	By:	/s/ Mark Colonnese
		Mark P. Colonnese
		Chief Financial Officer
		(Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.